We use cookies to enhance your experience. By continuing to browse this site you agree to our use of cookies. More info.
Antigenic drift causes sudden changes in influenza antiviral target proteins that cloak influenza virus from the immune system of vaccinated hosts. To maintain immunological recognition against diverse influenza subtypes, a yearly formulation change for influenza vaccines and concomitant antibody treatments is required.
It is crucial to understand the binding kinetics and epitope variety of different antibodies to influenza viral antigens to cure and control outbreaks. In this article, using only 2 µL per sample, researchers perform kinetic analysis and epitope characterization of various antibodies against Influenza A nucleoprotein (NP) and hemagglutinin (HA).
The influenza virus causes a highly infectious ailment known as “the flu.” Influenza A and B, two of the four varieties (Influenza A, B, C, and D), are the two most common flu viruses that affect humans. Both are extremely contagious and regularly cause seasonal epidemics. Influenza A viruses are also the only ones proven to cause flu outbreaks, with Influenza A viruses being linked to all five flu pandemics since 1900.
Since viruses are constantly evolving, studies of viral antibody and antigen binding and characterization are essential for managing and avoiding viral epidemics. Furthermore, these investigations contribute to our knowledge of viral antigenic drift and the variability of flu-related antibodies.
The influenza viral nucleoprotein is a structural protein that helps the virus replicate and adapt to its new environment. Antibodies that target NP proteins are extensively employed in ELISA, lateral flow assay (LFA), and direct fluorescent antibody tests for the identification of influenza viruses. Broad-spectrum influenza antibodies are especially needed for flu diagnostics due to the high frequency of antigenic drift or shift across various influenza strains.
Since antibodies can directly disrupt the virus’s attachment to the host cell receptor, the HA protein receptor-binding domain (RBD) is an important objective for vaccine development. Modifications in this protein are also necessary for vaccine development to continue.
Conventional methods like ELISA and western blot (WB) involve time-consuming washing and incubation processes and rely on tags for evaluation. SPR’s information content allows for more efficient creation of viral diagnostics and treatments, as compared to standard approaches.
Without the use of tags or labels, SPR allows a complete kinetic analysis of antibody-antigen interactions to comprehend, classify, and optimize antibody therapies. It also has epitope binning capabilities, which helps researchers better comprehend epitope variety and overlap.
Alto’s digital microfluidic (DMF) powered surface plasmon resonance (SPR) technology enables researchers to examine, create, and optimize vaccines and antibody therapies, among other things. SPR’s full kinetic characterization allows for a better understanding of antibody effectiveness and antigen drift. With sample needs as low as 2 µL per protein and automated on-cartridge serial dilutions, Alto speeds up analysis.
For use in SPR-based tests, Sino Biological offers recombinant antigen preparations for all WHO-recommended vaccination strains, including HA, NA, and nucleoproteins.
This article looks at kinetic and epitope characterization tests on Alto with five distinct antibodies to two influenza A nucleoproteins (NP) and two distinct antibodies to an influenza A hemagglutinin (HA) protein, undertaken in conjunction with Sino.
Alto’s on-screen setup instructions included the following steps:
Alto ran the commands and operations listed below automatically.
The binding and kinetic fits of the Influenza A Proteins to the immobilized Influenza A Antibodies resulted in good binding curves and kinetic parameter assessments. Figures 1 and 2 show a representative layer of single-cycle and multi-cycle kinetics.
The data was fitted to a one-to-one binding model, and the determined kinetic constants are shown in Table 1. The kinetic data shows that the three Influenza A Proteins have a high affinity for all of the Influenza A Antibodies evaluated.
Figure 1. Single-cycle kinetics of Influenza A protein binding to immobilized Influenza A Antibodies on Alto. Influenza A protein analyte was titrated from 1.2 nM to 100 nM. The black curve is the Langmuir 1:1 binding fit model analyzed in the Nicoya Analysis Software. Image Credit: Sino Biological Inc.
Figure 2. Multi-Cycle kinetics of Influenza A Protein binding to immobilized Influenza A Antibodies on Alto. Influenza A protein analyte was titrated from 2.4 nM to 200 nM. The black curve is the Langmuir 1:1 binding fit model analyzed in the Nicoya Analysis Software. Image Credit: Sino Biological Inc.
Table 1. Kinetic values measured using Alto data with the Nicoya analysis software. Source: Sino Biological Inc.
Sino Biological’s reagents’ epitope diversity was assessed using a sandwich assay and Capture methodology. Figures 3 and 4 show the outcomes of a 5x5 epitope bin, with “Bind” results indicating a distinct epitope focused on the antibodies. In regards to epitope characterization, kinetic values for each antibody were acquired using on-cartridge serial dilutions in the very same investigation.
Figure 3. Epitope characterization showing capturing of the Influenza A NP Protein antigen (green curve) to the immobilized surface antibody NP I followed by binding of the solution antibody to a different epitope of the antigen (purple - NP III). A lack of binding of the solution antibody in the purple - NP II curve indicates epitope overlap of NP II with NP I. Full regeneration is achieved by 10 mM glycine HCl pH 2.0 (orange curve returning the response to the baseline before antigen capture. Image Credit: Sino Biological Inc.
Figure 4. Epitope characterization analysis for Pan Influenza A Nucleoprotein Antibody binding to Influenza A Nucleoprotein Proteins Cat: 40205-V08B and 40208-V08B. Image Credit: Sino Biological Inc.
Alto was able to effectively characterize Sino Biological’s extremely specific antibodies and high-quality antigens using DMF-powered SPR to conduct kinetics and epitope analysis research. When compared to conventional characterization techniques, SPR speeds up the analysis of multiple interactions by eradicating the need for labels and lowering time-consuming preparation steps.
The information given here was collected in less than one week, highlighting the benefits of Alto’s ultra-low sample consumption combined with the use of high-quality reagents, like the amine coupling kit used in this application, and automated on-cartridge serial dilutions.
Alto’s high-throughput capabilities can speed up the research process by producing full kinetic data analysis and epitope binning experiments from as little as 2 µl of the sample while only needing less than 20 minutes of hands-on time per test.
Table 1. Sino Biological anti-NP and anti-HA antibodies (ligands). Source: Sino Biological Inc.
Table 2. Sino Biological recombinant proteins (analytes). Source: Sino Biological Inc.
Sino Biological is an international reagent supplier and service provider. The company specializes in recombinant protein production and antibody development. All of Sino Biological's products are independently developed and produced, including recombinant proteins, antibodies and cDNA clones. Sino Biological is the researchers' one-stop technical services shop for the advanced technology platforms they need to make advancements. In addition, Sino Biological offers pharmaceutical companies and biotechnology firms pre-clinical production technology services for hundreds of monoclonal antibody drug candidates.
Sino Biological is committed to providing high-quality recombinant protein and antibody reagents and to being a one-stop technical services shop for life science researchers around the world. All of our products are independently developed and produced. In addition, we offer pharmaceutical companies and biotechnology firms pre-clinical production technology services for hundreds of monoclonal antibody drug candidates. Our product quality control indicators meet rigorous requirements for clinical use samples. It takes only a few weeks for us to produce 1 to 30 grams of purified monoclonal antibody from gene sequencing.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.
Last updated: May 17, 2022 at 2:20 AM
Please use one of the following formats to cite this article in your essay, paper or report:
Sino Biological Inc.. (2022, May 17). Characterizing the kinetics and epitopes of influenza antiviral targets. News-Medical. Retrieved on May 28, 2022 from https://www.news-medical.net/whitepaper/20220509/Characterizing-the-kinetics-and-epitopes-of-influenza-antiviral-targets.aspx.
Sino Biological Inc.. "Characterizing the kinetics and epitopes of influenza antiviral targets". News-Medical. 28 May 2022. <https://www.news-medical.net/whitepaper/20220509/Characterizing-the-kinetics-and-epitopes-of-influenza-antiviral-targets.aspx>.
Sino Biological Inc.. "Characterizing the kinetics and epitopes of influenza antiviral targets". News-Medical. https://www.news-medical.net/whitepaper/20220509/Characterizing-the-kinetics-and-epitopes-of-influenza-antiviral-targets.aspx. (accessed May 28, 2022).
Sino Biological Inc.. 2022. Characterizing the kinetics and epitopes of influenza antiviral targets. News-Medical, viewed 28 May 2022, https://www.news-medical.net/whitepaper/20220509/Characterizing-the-kinetics-and-epitopes-of-influenza-antiviral-targets.aspx.
A brief overview of immunologic testing for COVID-19
Advancing virus research with specialized tools
Anti-cancer drug targets: Tools for research
Applying molecular interaction technology in SPR and BLI research
Cancer treatment: Exploring various cytokine and anticytokine therapies
Colony-stimulating factors and receptors: Potential for cancer and inflammatory disorder treatment
Combating the consistent emergence of new SARS-CoV-2 variants
COVID-19: Devising research tools for study
Creating afucosylated antibodies with increased antibody-dependent cellular cytotoxicity (ADCC)
Generating monoclonal antibodies via B cell cloning
High Purity Recombinant Lipases for Host Cell Protein Assays
IL-1 Cytokine Primes Innate Immunity
IL-18: A Link Between Innate and Adaptive Immunity
IL-6: A Critical Inflammatory, Pleiotropic Cytokine
Influenza antigen testing: Antibodies for immunodetection
Influenza: Immunodetection and vaccine development
Influenza: Research Tools for the Virus
Interleukin-2 (IL-2): Why Does This Cytokine Have Immunostimulatory and Immunoregulatory Functions?
NKG2 proteins: Checkpoint targets for immunotherapy
Novel Coronavirus (SARS-CoV-2) Reagents for Research
Optimizing PK/ADA assays with anti-idiotype antibodies
Producing and utilizing antibody fragments
Recombinant antibodies: Expression, application and formats
Research tools in immune checkpoint therapies
The application of cytokines within cancer immunotherapy
The challenges faced in recombinant protein expression
The increasing use of bispecific antibodies in antibody therapeutics
Understanding the Interleukin-1 family: Central mediators of innate immunity and inflammation
Utilizing insect cells in recombinant protein expression
Utilizing stem cells to support and aid cancer therapy
VEGFs and their receptors: Key mediators in the nervous and vascular systems
Viral research using recombinant antigens from Sino Biological
Irene Walsh and Professor Claire Smith
In this interview, News Medical speak to Irene Walsh, the director of Product, Design & Content, and 3D4Medical at Elsevier, and Professor Claire Smith, Head of Anatomy at Brighton and Sussex Medical School, about the real-world applications of the Complete Anatomy female model, the most advanced full female anatomy model in the world.
In this interview, we talk to Takayuki Baba about ongoing research using artificial intelligence to achieve earlier diagnosis of pancreatic cancer.
In this interview, we speak to Matt Walz, CEO of Trialbee, about the importance of improving patient recruitment and retention within clinical trials.
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.
This site complies with the HONcode standard for trustworthy health information: verify here.
News-Medical.net - An AZoNetwork Site
Owned and operated by AZoNetwork, © 2000-2022